Phase I trial data for remyelinating antibody in MS released

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Phase I trial data for remyelinating antibody in MS released

Post by MSUK »

Acorda Therapeutics has today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied. Based on this, the Company intends to advance clinical development of rHIgM22..... Read More - http://www.ms-uk.org/emergingtherapies
MS-UK - http://www.ms-uk.org/
User avatar
carolsue
Family Elder
Posts: 175
Joined: Sun Jul 25, 2004 2:00 pm
Location: Sunnydale, USA

Re: Phase I trial data for remyelinating antibody in MS rele

Post by carolsue »

Science magazine has an informative article about so-called natural antibodies, including rHIgM22. Fascinating. And reminds me that we understand so so little about the immune system! http://www.sciencemag.org/content/347/6226/1058.full
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Drug Pipeline”